Olympus Launches SecureFlex FNB Needle for U.S. Pancreatic Cancer Diagnostics
Event summary
- Olympus Corp. of the Americas launched the SecureFlex™ FNB needle for U.S. endoscopic ultrasound-guided biopsies on January 28, 2026.
- The device is designed for precision sampling of pancreatic cancer and other hard-to-reach lesions.
- SecureFlex is available in 19G, 22G, and 25G sizes, featuring a Dual-Beveled Raptor™ Tip and Nitinol construction for enhanced performance.
- Olympus will showcase the product at the Cedars-Sinai Endoscopy Symposium and Orlando Live Endoscopy 2026.
The big picture
Olympus' SecureFlex launch aligns with the growing demand for high-quality tissue sampling in pancreatic cancer treatment, driven by advances in molecularly targeted therapies. The product expands Olympus' GI portfolio, reinforcing its position in endoscopic ultrasound technology. The U.S. market, with its high adoption of minimally invasive diagnostics, presents a significant revenue opportunity.
What we're watching
- Adoption Pace
- How quickly SecureFlex will be adopted by U.S. gastroenterologists, particularly for pancreatic cancer diagnostics.
- Competitive Response
- Whether competitors like Boston Scientific or Cook Medical will introduce rival products or lower prices.
- Regulatory Scrutiny
- The level of FDA oversight on single-use biopsy devices, given the risks of complications like infection or bleeding.
Our editorial coverage:
Related topics